top of page

​

1.png
Air Pressure

 FDA-Cleared for Your Safety

The Quamvis 320 by OxyHealth is an FDA-cleared Class II medical device, meaning it meets strict U.S. standards for safety, performance, and manufacturing quality. It operates at 1.3 ATA, offering a low-pressure, mild hyperbaric environment approved for use under the supervision of a licensed practitioner.

 

  • Class II clearance ensures regulatory oversight and clinical-grade construction

  • Materials and design meet FDA, ASME-PVHO, and NFPA 99 requirements

  • Backed by over 20 years of safe, global use in thousands of clinics and hospitals

​

Quamvis 320 is an FDA-cleared Class II hyperbaric chamber for mild hyperbaric therapy. While HBOT shows promise for neurological and inflammatory conditions, it is not FDA-approved for autism, PTSD, or TBI at this time. All therapy is provided under physician oversight in accordance with best practice guidelines.

Image by Joshua Earle

Quamvis 320
 
Safe, non-invasive, and available now in Ashburn!
 
 
At Brain Treatment Center Ashburn, we’re proud to introduce the Quamvis 320 by OxyHealth, a mild-pressure, Class II FDA-cleared chamber designed for safe, comfortable, and effective oxygen therapy sessions. Operating at just 1.3 ATA, this system offers enhanced healing potential while minimizing risks common with higher-pressure chambers.
 
 
Why Quamvis 320 Is a Safe Choice
 
 

  • Operates at only 1.3 times atmospheric pressure—gentle on the ears, lungs, and nervous system

  • Meets FDA, ASME, and NFPA safety standards—including continuous oxygen purity monitoring

  • Spacious, clear chamber reduces feelings of confinement and supports patient comfort  

Hyperbaric Oxygen Therapy (HBOT)


Autism Spectrum Disorder
 

  • A landmark randomized trial showed children receiving 40 sessions at 1.3 ATA and 24% oxygen demonstrated significant improvements in social interaction, receptive language, sensory function, and eye contact compared to controls  .

  • Other open-label and case studies suggest reductions in neuroinflammation and oxidative stress .

 
 
PTSD & Mild Traumatic Brain Injury (TBI)
 

  • A 2024 randomized trial found 40 HBOT sessions significantly improved neurobehavioral symptoms, including anxiety, sleep, headache, and sensory complaints (mean decrease in NSI = 7 points vs. sham, p=0.01)  .

  • A systematic review confirms statistically and clinically meaningful symptom improvement in PTSD across multiple RCTs  .

 
 
Additional Conditions
 

  • Evidence suggests potential cognitive, fatigue, and neuroplasticity benefits in long-COVID, chronic fatigue, Lyme disease, and other inflammatory neurologic conditions  .

Potential Benefits (Clinical Evidence-Based)

  
Our HBOT offers the potential to support:
 

  • Improved oxygen delivery to brain and tissues

  • Reduced inflammation and better immune modulation

  • Neurovascular support, possibly enhancing cognitive thinking and emotional regulation

  • Accelerated recovery from neurological challenges such as autism, PTSD, TBI, chronic fatigue, and more

 
 
HBOT is not a cure but a pathway to wellness enhancement when used alongside other clinical therapies.

How We Deliver HBOT
 
 

  • Consultation & Screening with a licensed practitioner, including BP & vital checks

  • Custom session plans, typically 60–75 minutes long, overseen by trained staff

  • Integration with Other Therapies: MeRT, cold laser, red light therapy, and functional health services

What the Research Shows

quamvis320-hyperbaric-chamber.jpg
bottom of page